Markets
Yiwen Lu

Stocks of mortgage giants rise on privatization prospects

Shares of Freddie Mac jumped nearly 40% at market open on Wednesday. Fannie Mae stock rose about 30% and were the top-performing US stocks in the premarket. The two major government-sponsored enterprises, which have been under the control of the Federal Housing Finance Agency since the 2008 financial crisis, are set to benefit from a Trump presidency.

Republicans have hoped that Trump would fulfill a longstanding GOP goal to privatize the two companies, which he attempted to do in 2019. However, Democrats worry that doing so would add to the already high mortgage rates in the most unaffordable housing market in decades.

In a note, Bloomberg Intelligence analyst Ben Elliott said that getting the GSEs out of government conservatorship “remains at best a 2026-27 prospect,” and is contingent on the administration’s pick of Treasury secretary and Federal Housing Finance Agency director.

More Markets

See all Markets
markets

Rocket Lab slips with other momentum stocks despite DOD hypersonic test deal, new analyst “buy” call

Rocket Lab slipped early Thursday along with other momentum stocks, despite announcing a new $190 million deal for 20 tests of hypersonic rockets for the Department of Defense and picking up a new bullish analyst call.

The commercial space launch company called the deal to launch 20 hypersonic test flights over a four-year period in collaboration with Kratos Defense its “single largest launch agreement yet.”

Separately, analysts at brokerage firm Clear Street initiated coverage of Rocket Lab with a “buy” rating and an $88 price target — essentially the same as Wall Street’s $88.38 consensus, according to FactSet. That implies upside of about 27% for the stock compared to yesterday’s close. Clear Street analysts wrote:

“Despite shares rising 289% (vs. 26% for the NASDAQ) over the past year, we see further upside. Our $88 target is based on 20x 2030E EV/Sales, in line with the ~30x NTM EV/Revenue average over the past year when discounted to present value. We anchor on 2030E to capture the payoff from ~16 annual Neutron launches following a multi-year investment cycle. Our outlook incorporates estimated dilution and proceeds from the $1B equity distribution agreement announced on 3/17/2026.”

The favorable headlines for Rocket Lab weren’t enough to help the shares overcome a general downdraft for high-beta momentum stocks such as itself. They are getting hammered early on the deteriorating situation in the Mideast war.

Separately, analysts at brokerage firm Clear Street initiated coverage of Rocket Lab with a “buy” rating and an $88 price target — essentially the same as Wall Street’s $88.38 consensus, according to FactSet. That implies upside of about 27% for the stock compared to yesterday’s close. Clear Street analysts wrote:

“Despite shares rising 289% (vs. 26% for the NASDAQ) over the past year, we see further upside. Our $88 target is based on 20x 2030E EV/Sales, in line with the ~30x NTM EV/Revenue average over the past year when discounted to present value. We anchor on 2030E to capture the payoff from ~16 annual Neutron launches following a multi-year investment cycle. Our outlook incorporates estimated dilution and proceeds from the $1B equity distribution agreement announced on 3/17/2026.”

The favorable headlines for Rocket Lab weren’t enough to help the shares overcome a general downdraft for high-beta momentum stocks such as itself. They are getting hammered early on the deteriorating situation in the Mideast war.

markets

Uber will invest $1.25 billion in Rivian in a new robotaxi deal

EV maker Rivian surged more than 9% in premarket trading on Thursday following an announcement that Uber will invest up to $1.25 billion in the company through 2031 as part of a robotaxi partnership.

The deal will begin with an initial $300 million investment, and Uber will purchase 10,000 autonomous versions of the R2. Uber will have the option to buy 40,000 more in 2030.

The R2 is Rivian’s smaller, less expensive model and is set to roll out to buyers in the second quarter of this year.

Per a company filing on Thursday, Rivian “no longer expects to be adjusted EBITDA positive in 2027 due to an expected increase in R&D spend associated with the acceleration of its autonomy roadmap.”

Uber, which has more than 20 autuonomous vehicle partnerships ranging from Alphabet’s Waymo to Baidu, has become a dominant robotaxi force.

Rivian had first hinted at robotaxi plans at its Autonomy and AI Day in December.

The R2 is Rivian’s smaller, less expensive model and is set to roll out to buyers in the second quarter of this year.

Per a company filing on Thursday, Rivian “no longer expects to be adjusted EBITDA positive in 2027 due to an expected increase in R&D spend associated with the acceleration of its autonomy roadmap.”

Uber, which has more than 20 autuonomous vehicle partnerships ranging from Alphabet’s Waymo to Baidu, has become a dominant robotaxi force.

Rivian had first hinted at robotaxi plans at its Autonomy and AI Day in December.

markets

Lilly reports encouraging trial results for its next-gen GLP-1 shot

Eli Lilly released late-stage trial results for its next-generation GLP-1 shot, retatrutide, showing the drug helped patients lose more weight than anything currently on the market.

Patients taking the highest dose of retatrutide, 12 milligrams, lost 16.8% of their body weight after 40 weeks, more than its current bestseller, tirzepatide. The results also showed significant reduction in blood sugar levels.

The stock was flat in premarket trading following the news.

Lillys tirzepatide, sold under the brand names Zepbound and Mounjaro, is currently the most sold drug in the world. The companys sales have now outpaced its top rival, Novo Nordisk, which was the first to bring a GLP-1 to market but has seen sales decelerate as competitors have muscled in.

Still, some expect Lillys winning streak may not last forever. Analysts at HSBC gave the stock a rare downgrade earlier this week, citing a crowded market, among other factors.

markets

Gold and silver dip amid inflation concerns and ongoing Iran war

Often seen as safe havens through times of uncertainty, precious metals arent acting that way today, as oil prices spike amid escalations in the Iran war, compounding inflationary concerns and sending the SPDR Gold Shares ETF and iShares Silver Trust down 3.4% and 6.6%, respectively, as of 6:55 a.m. ET.

Though the Fed kept rates steady yesterday, as was universally expected, officials raised their forecasts for inflation — a move that seems to have spooked investors, who had already been taking risk off the table in recent weeks. With Brent crude north of $114 per barrel this morning, investors look to be bracing for further inflationary shock and are dumping gold and silver, as implied odds of a Fed rate cut in June plummeted on prediction markets from 60% on February 23 to just 16% this morning.

The shiny metal slump is already weighing on mining stocks like Anglogold Ashanti, Newmont, Wheaton Precious Metals, and Agnico Eagle, which are all plunging in premarket trading.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.